PATENT CLAIM ANALYSIS

Application Number: 16198141
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "094000"]

Abstract:
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Claim (Index 1):
A method of treating drop seizures in a patient with Lennox-Gastaut syndrome and Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the dose of the CBD is 20 mg/kg/day.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.51786
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14881969', '15449535', '15449402', '16090039', '15449177']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8097120507345219
- 35 USC 102 Novelty (BERT): 0.6231082014891919
- Combined Prediction Score: 0.791051665809989
- Mean Citation Score: 519.5925219999998
- Max Citation Score: 579.3248
- Similarity Product: 526.7631376813888

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test